Italia markets close in 8 hours 26 minutes

AstraZeneca PLC (AZN.L)

LSE - LSE Prezzo differito. Valuta in GBp.
Aggiungi a portafoglio
7.786,00+154,00 (+2,02%)
Al 4:45PM BST. Mercato aperto.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno76.100

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director4,39MN/D1959
Mr. Marc DunoyerCFO & Exec. Director2,45MN/D1952
Ms. Pam P. ChengExec. Vice-Pres of Operations & Information TechnologyN/DN/D1971
Thomas Kudsk LarsenHead of Investor RelationsN/DN/DN/D
Mr. Jefrey PottExec. VP of HR & Gen. CounselN/DN/DN/D
Ms. Katarina AgeborgExec. VP of Sustainability & Chief Compliance OfficerN/DN/DN/D
Dr. Menelas PangalosExec. Vice-Pres of BioPharmaceuticals R&DN/DN/DN/D
Dr. Ruud DobberExec. Vice-Pres of BioPharmaceuticals Bus. UnitN/DN/DN/D
Dr. Susan Mary Galbraith M.D., Ph.D.Sr. VP and Head of Research, Early Devel. & Oncology R&DN/DN/D1966
Dr. David B. Goldstein Ph.D.Chief AdviserN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; and Alchemab to enhance prostate cancer research. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di AstraZeneca PLC al 30 aprile 2021 è 5. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 7; diritti degli azionisti: 1; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.